CYBERKINETICS PROVIDES UPDATE ON BRAINGATE SYSTEM PILOT CLINCAL TRIALS

Cyberkinetics Neurotechnology Systems, Inc. today provided a quarterly update on two pilot clinical studies currently underway of the Company's BrainGate Neural Interface System. The first trial is for those with quadriplegia due to spinal cord injury, stroke or muscular dystrophy ("SCI trial"); and the second is for those diagnosed with ALS (amyotrophic lateral sclerosis or Lou Gehrig's disease) or other motor neuron diseases ("ALS trial").
Genetic Engineering News